Effect of Cinacalcet on Hypercalcemia and Bone Mineral Density in Renal Transplanted Patients With Secondary Hyperparathyroidism
Authors:
- José-Vicente TorregrosaJTJosé-Vicente Torregrosa
- David FusterDFDavid Fuster
- Alex Gutierrez-DalmauAGAlex Gutierrez-Dalmau
- Federico OppenheimerFOFederico Oppenheimer
- José M. CampistolJCJosé M. Campistol
- 15 August 2008
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Transplantation
- Vol. 86 (3) , 413-417
Abstract
Persistent secondary hyperparathyroidism (SHP) is the most frequent cause of hypercalcemia observed in approximately 10% of renal transplanted (RT) patients 1 year after surgery. Persistent SHP with hypercalcemia is an important factor of bone loss after renal transplantation. This study prospectively evaluates the effects of Cinacalcet therapy on serum calcium (SCa) and parathyroid hormone (PTH) blood levels, and basically on bone mineral density (BMD) in RT patients with persistent hyperparathyroidism. Nine RT patients (eight women, one man) with allograft function more than 6 months were included based on total SCa more than 10.5 mg/dL and intact parathyroid hormone (iPTH) concentration more than 65 pg/mL. After inclusion, patients started on a single daily oral dose of 30 mg of Cinacalcet. At inclusion and every study visit blood levels of creatinine, Ca, P, alkaline phosphatase, iPTH 1,25- dihydroxyvitamin D3, and 25-hydroxyvitamin D3 were assessed. Baseline and at the end of study radial BMD were measured. Study follow-up was 12 months. During the study period, SCa decreased from 11.72±0.39 to 10.03±0.54 mg/dL (P<0.001). iPTH decreased from 308.85±120.12 to 214.66±53.75 mg/dL (P<0.05). The mean serum creatinine decreased from 1.58±0.34 to 1.25±0.27 mg/dL (P=0.03) and the mean radial BMD increased from 0.881±0.155 to 0.965±0.123 gr/cm2 (P<0.05). There were no significant changes in the other parameters assessed. One patient was excluded for gastrointestinal intolerance. In RT patients with hypercalcemia secondary to persistent SHP, Cinacalcet corrects hypercalcemia and PTH, simultaneously improving BMD.Keywords
This publication has 28 references indexed in Scilit:
- Fracture Risk after Parathyroidectomy among Chronic Hemodialysis PatientsJournal of the American Society of Nephrology, 2007
- Elevated calcium phosphate product after renal transplantation is a risk factor for graft failureClinical Transplantation, 2007
- Preliminary Experience With Cinacalcet Use in Persistent Secondary Hyperparathyroidism After Kidney TransplantationTransplantation, 2007
- Cinacalcet Chloride Is Efficient and Safe in Renal Transplant Recipients with Posttransplant HyperparathyroidismTransplantation, 2006
- Drug Insight: renal indications of calcimimeticsNature Clinical Practice Nephrology, 2006
- Early Calcification of Renal Allografts Detected by Protocol Biopsies: Causes and Clinical ImplicationsAmerican Journal of Transplantation, 2005
- Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidismNephrology Dialysis Transplantation, 2005
- Natural history of parathyroid function and calcium metabolism after kidney transplantation: a single-centre studyNephrology Dialysis Transplantation, 2004
- Disparate effects of mild, moderate, and severe secondary hyperparathyroidism on cancellous and cortical bone in rats with chronic renal insufficiencyBone, 1998
- Retrospective study on the usefulness of radius and lumbar bone density in the separation of hemodialysis patients with fractures from those without fracturesBone, 1996